RGNX - REGENXBIO Inc.
| Previous Close | 49.85 |
| Open | 50.03 |
| Bid | 0.00 x 1000 |
| Ask | 62.65 x 800 |
| Day's Range | 48.75 - 51.00 |
| 52 Week Range | 38.56 - 83.45 |
| Volume | 567,348 |
| Avg. Volume | 570,809 |
| Market Cap | 1.8B |
| Beta (3Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.05 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.17 |
- Zacks•20 days ago
Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?
Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Regenxbio Inc Earnings Call
- Zacks•2 months ago
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Motley Fool•2 months ago
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Motley Fool•2 months agoRegenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript
RGNX earnings call for the period ending March 31, 2019.
- Motley Fool•3 months ago
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
- Simply Wall St.•3 months ago
Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain?
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. F...
- Zacks•3 months ago
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- Motley Fool•4 months ago
3 Small-Cap Biotech Stocks to Watch Now
These under-the-radar stocks could be poised to make big moves in the coming months.
- GlobeNewswire•4 months ago
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Motley Fool•4 months ago
Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?
Roche and Biogen are spending big bucks on gene therapy biotech stocks.
- Zacks•5 months ago
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Motley Fool•5 months ago
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of RGNX earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Regenxbio Inc Earnings Call
Motley Fool•5 months agoRegenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript
RGNX earnings call for the period ending December 31, 2018.
- Zacks•5 months ago
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
- Zacks•5 months ago
5 Gene Therapy Stocks to Enrich Your Portfolio
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
- GlobeNewswire•6 months ago
Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 Regenxbio Inc Earnings Call
- Simply Wall St.•6 months ago
REGENXBIO Inc. (NASDAQ:RGNX): Time For A Financial Health Check
REGENXBIO Inc. (NASDAQ:RGNX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is RGNX will Read More...
Market Realist•7 months agoWhy Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to reach $15.19 at the close of market on December 12, reflecting a ~313% year-to-date rise.
Market Realist•8 months agoArrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date
Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to $12.95 at the close of market on November 21, 2018, a ~252% rise year-to-date. On November 21, Arrowhead Pharmaceuticals closed at $12.95, ~42% below the 52-week high of $22.39 it reached on September 6. Arrowhead Pharmaceuticals hit its 52-week low of $3.01 on December 13, 2017.
- Business Wire•8 months ago
Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
Rocket Pharmaceuticals, Inc. (RCKT), a leading U.S.-based multi-platform gene therapy company, and REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease using REGENXBIO’s NAV AAV9 vector, as well as exclusive options for two additional NAV AAV vectors for the treatment of Danon disease.
